Innovation Kyoto 2016 Investment Limited Partnership" ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto-iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi) as the general partner, has made an additional investment inToregem BioPharma Co., Ltd (Head office: Sakyo-ku, Kyoto; Representative Director: Honoka Kiso) through a third-party allocation of new shares.

Overview of this investment
Toregem is a drug discovery startup in the field of dentistry, founded by Kyoto University in May 2020. Kyoto University and Toregem have previously demonstrated the role of USAG-1, a molecule that inhibits the function of bone morphogenetic proteins such as BMPs, in tooth development and that neutralizing antibodies against USAG-1 restore missing teeth together with alveolar bone in an animal model of edentulism.

Tregem has recently raised a Series B round of funds through a third-party allotment of new shares. Including subsidies from the AMED (Japan Agency for Medical Research and Development), which adopted the "Drug Discovery Venture Ecosystem Enhancement Project (Drug Discovery Venture Open Call) (4th round)" program in FY2024, this round of financing amounts to a maximum of approximately 1.5 billion yen.

With this financing, Toregem will conduct Phase I clinical trials and prepare for Phase II clinical trials for TRG035 (humanized anti-USAG-1 antibody), which it is independently developing, to further accelerate the clinical development of the world's first tooth regeneration treatment drug.

Kyoto-iCAP has made an additional investment of 100 million yen in the hope that TRG035, developed by Tregem, will serve as a good news for patients suffering from dental problems, including edentulous patients. In addition to Kyoto-iCAP, Tohoku University Venture Partners, Inc. (headquartered in Sendai City, Miyagi Prefecture; Tetsuro Higuchi, Representative Director), JIC Venture Growth Investments, Inc. Venture Management LLC (Head Office: South San Francisco, CA, President William Watt), Mitsubishi UFJ Capital Limited (Head Office: Chuo-ku, Tokyo, Representative Director: Takuro Kojima), Kyoto Capital Partners Co, (Head Office: Kyoto City, Representative Director: Hiroshi Yamamoto), Sankin Corporation (Head Office: Osaka City, Representative Director: Kazumi Kinumaki), and Greencore Corporation (Head Office: Shibuya-ku, Tokyo, Representative Director: Ryusuke Honjo) participated in this event.

About Tregem Biopharma, Inc.
Establishment : May 12, 2020
Business ：Development of tooth regeneration treatment drugs
Head Office Address : 448-5 Kaji-cho, Imadegawa-sagaru, Kawaramachi-Dori, Kamigyo-ku, Kyoto, Japan
Representative Director : Honoka Kiso
HP: https://toregem.co.jp/

About Kyoto University Innovation Capital Co., Ltd. (Kyoto-iCAP)
As a wholly-owned subsidiary of Kyoto University, KYOTO-iCAP provides investment and other business support to companies that utilize research results generated by Kyoto University and other national universities. We currently operate the KYOTO-iCAP No. 1 Fund (established in January 2016) with a total value of 16 billion yen and the Innovation Kyoto 2021 Investment Limited Partnership ("KYOTO-iCAP No. 2 Fund") (established in January 2021) with a total value of 18.1 billion yen. The No. 1 Fund has a maturity of up to 20 years, and the No. 2 Fund has a maturity of up to 17 years, making it possible to provide long-term support for the practical application of research results from Kyoto University, which has strengths in basic research. In addition, a portion of the funds in the No. 2 Fund will be invested in ventures originating from national universities other than Kyoto University.

Contact information for inquiries
Kyoto University Innovation Capital Co., Ltd.
36-1, Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317, Japan
Osami Kono, Senior Officer, Business Development Department
E-mail: info@kyoto-icap.co.jp
TEL: 075-753-7588